[1]. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
[2]. Hidalgo, M., et al., Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology, 2015. 15(1): p. 8-18.
[3]. Rawla, P., T. Sunkara and V. Gaduputi, Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol, 2019. 10(1): p. 10-27.
[4]. Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.
[5]. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 1999. 117(6): p. 1463-84.
[6]. Mizrahi, J.D., et al., Pancreatic cancer. Lancet, 2020. 395(10242): p. 2008-2020.
[7]. Clark, C.E., et al., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res, 2007. 67(19): p. 9518-27.
[8]. Provenzano, P.P., et al., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 2012. 21(3): p. 418-29.
[9]. Stromnes, I.M., et al., Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut, 2014. 63(11): p. 1769-81.
[10]. Stromnes, I.M., et al., T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res, 2017. 5(11): p. 978-991.
[11]. Topalian, S.L., et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012. 366(26): p. 2443-54.
[12]. Royal, R.E., et al., Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother, 2010. 33(8): p. 828-33.
[13]. Thomas, D. and P. Radhakrishnan, Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer, 2019. 18(1): p. 14.
[14]. Alderton, G.K., Microenvironment: An exercise in restraint. Nat Rev Cancer, 2014. 14(7): p. 449.
[15]. Feig, C., et al., The pancreas cancer microenvironment. Clin Cancer Res, 2012. 18(16): p. 4266-76.
[16]. Clark, C.E., et al., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res, 2007. 67(19): p. 9518-27.
[17]. Steele, C.W., et al., Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer, 2013. 108(5): p. 997-1003.
[18]. Puleo, F., et al., Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology, 2018. 155(6): p. 1999-2013.e3.
[19]. Burnet, F.M., The concept of immunological surveillance. Prog Exp Tumor Res, 1970. 13: p. 1-27.
[20]. Ostrand-Rosenberg, S., Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev, 2008. 18(1): p. 11-8.
[21]. Lu, Q., et al., Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer. Medicine (Baltimore), 2021. 100(12): p. e24957.
[22]. Ino, Y., et al., Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer, 2013. 108(4): p. 914-23.
[23]. Wang, L., et al., Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer. J Cancer, 2020. 11(22): p. 6530-6544.
[24]. Gentles, A.J., et al., The prognostic landscape of genes and infiltrating immune cells across human cancers. Vol. 21. 2015. 938-945.
[25]. Ali, H.R., et al., Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med, 2016. 13(12): p. e1002194.
[26]. Bense, R.D., et al., Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst, 2017. 109(1).
[27]. Gentles, A.J., et al., The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med, 2015. 21(8): p. 938-945.
[28]. Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-50.
[29]. Malta, T.M., et al., Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018. 173(2): p. 338-354.e15.
[30]. Tan, T.Z., et al., Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med, 2014. 6(10): p. 1279-93.
[31]. Hanzelmann, S., R. Castelo and J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 2013. 14: p. 7.
[32]. Ladanyi, A., Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res, 2015. 28(5): p. 490-500.
[33]. Wu, Z., et al., The Landscape of Immune Cells Infiltrating in Prostate Cancer. Front Oncol, 2020. 10: p. 517637.
[34]. Martinez-Rodriguez, M., A.K. Thompson and C. Monteagudo, A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma. Histopathology, 2014. 65(5): p. 726-8.
[35]. Moretta, A., et al., Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends in Immunology, 2005. 26(12): p. 668-675.
[36]. Martín-Fontecha, A., et al., Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming. Nature Immunology, 2004. 5(12): p. 1260-1265.
[37]. Ruggeri, L., et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002. 295(5562): p. 2097-100.
[38]. Moretta, L., et al., Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011. 117(3): p. 764-71.
[39]. Hahn, S.A., et al., Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res, 1996. 56(3): p. 490-4.
[40]. Hahn, S.A., et al., DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 1996. 271(5247): p. 350-3.
[41]. Sunamura, M., et al., Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg, 2002. 9(1): p. 32-8.
[42]. Pylayeva-Gupta, Y., et al., IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov, 2016. 6(3): p. 247-55.
[43]. Waters, A.M. and Der CJ, KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med, 2018. 8(9).